MedTrace Logo

Assessment of Delphinol® Dose on Vascular Function

NCT07196059 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-29

No results posted yet for this study

Summary

Maqui berry standardized extract (e.g. Delphinol®) has been used with success to modulate blood glucose and associated variables at a dosage of 450mg daily. Lower dosages have also been used with favorable effects. However, it is unknown what dosage is optimal for positively impacting vascular function. The purpose of this study is to determine the impact of Maqui berry standardized extract (e.g. Delphinol®) at varying dosages on vascular function assessed using the perfusion index, Vendys, and blood nitrate/nitrite concentrations.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Delphinol

Contains maqui berry powder

DIETARY_SUPPLEMENT

Placebo

Contains cellulose

Sponsors & Collaborators

  • Anklam-Extrakt GmbH

    collaborator UNKNOWN

  • University of Memphis

    lead OTHER

Principal Investigators

  • Richard Bloomer, PhD · University of Memphis

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-05
Primary Completion
2020-03-24
Completion
2020-03-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07196059 on ClinicalTrials.gov